Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Doshi

Showing results (51-60 of 144) with videos related to

Pageof 15
Sort By:
BMJ (Clinical Research Ed.)|January 26, 2008
Preventing flu-like illness: Reason for optimismPeter Doshi
BMJ (Clinical Research Ed.)|December 10, 2009
Neuraminidase inhibitors--the story behind the Cochrane reviewPeter Doshi
BMJ (Clinical Research Ed.)|May 8, 2024
Revolving doors: board memberships, hedge funds, and the FDA chiefs responsible for regulating industryPeter Doshi
BMJ (Clinical Research Ed.)|May 3, 2014
Authors' reply to DunningPeter Doshi, Tom Jefferson
BMJ (Clinical Research Ed.)|April 12, 2014
Multisystem failure: the story of anti-influenza drugsTom Jefferson, Peter Doshi
BMJ Open|March 1, 2013
Clinical study reports of randomised controlled trials: an exploratory review of previously confidential industry reportsPeter Doshi, Tom Jefferson
JAMA Internal Medicine|March 9, 2016
Neuraminidase Inhibitors and Influenza InfectionPeter Doshi, Tom Jefferson
BMJ (Clinical Research Ed.)|July 1, 2010
WHO and pandemic flu. Another question for GSKPeter Doshi, Tom Jefferson
BMJ (Clinical Research Ed.)|July 1, 2010
WHO and pandemic flu. Time for change, WHOTom Jefferson, Peter Doshi
Journal of Evaluation in Clinical Practice|July 15, 2023
How the case counting window affected vaccine efficacy calculations in randomized trials of COVID-19 vaccinesPeter Doshi, Kaiser Fung
Pageof 15

Showing results (51-60 of 144) with videos related to

Sort By:
Pageof 15
BMJ (Clinical Research Ed.)|January 26, 2008
Preventing flu-like illness: Reason for optimismPeter Doshi
BMJ (Clinical Research Ed.)|December 10, 2009
Neuraminidase inhibitors--the story behind the Cochrane reviewPeter Doshi
BMJ (Clinical Research Ed.)|May 8, 2024
Revolving doors: board memberships, hedge funds, and the FDA chiefs responsible for regulating industryPeter Doshi
BMJ (Clinical Research Ed.)|May 3, 2014
Authors' reply to DunningPeter Doshi, Tom Jefferson
BMJ (Clinical Research Ed.)|April 12, 2014
Multisystem failure: the story of anti-influenza drugsTom Jefferson, Peter Doshi
BMJ Open|March 1, 2013
Clinical study reports of randomised controlled trials: an exploratory review of previously confidential industry reportsPeter Doshi, Tom Jefferson
JAMA Internal Medicine|March 9, 2016
Neuraminidase Inhibitors and Influenza InfectionPeter Doshi, Tom Jefferson
BMJ (Clinical Research Ed.)|July 1, 2010
WHO and pandemic flu. Another question for GSKPeter Doshi, Tom Jefferson
BMJ (Clinical Research Ed.)|July 1, 2010
WHO and pandemic flu. Time for change, WHOTom Jefferson, Peter Doshi
Journal of Evaluation in Clinical Practice|July 15, 2023
How the case counting window affected vaccine efficacy calculations in randomized trials of COVID-19 vaccinesPeter Doshi, Kaiser Fung
Pageof 15